SiBone (NASDAQ:SIBN) Receives "Overweight" Rating from Cantor Fitzgerald

Key Points

• SiBone's stock has received an "overweight" rating from Cantor Fitzgerald, with a price target of $25, indicating a potential upside of 39.66% from its current price.
• In recent analyses, both Needham & Company and Truist Financial have reiterated positive ratings on SiBone, with price targets of $24.00 and $22.00 respectively.
• The company recently reported earnings, beating expectations with a revenue of $48.63 million for the quarter and a loss of ($0.14) earnings per share.

Cantor Fitzgerald restated their overweight rating on shares of SiBone (NASDAQ:SIBN - Free Report) in a research note published on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $25.00 price objective on the stock. Cantor Fitzgerald also issued estimates for SiBone's FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.32) EPS.

A number of other equities analysts have also weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Truist Financial upped their target price on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th.

SiBone Trading Down 3.9%

SiBone stock traded down $0.64 during mid-day trading on Tuesday, hitting $15.68. 371,646 shares of the company's stock were exchanged, compared to its average volume of 455,122. The firm has a market capitalization of $676.44 million, a P/E ratio of -28.00 and a beta of 0.91. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The company has a quick ratio of 7.26, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. The company's 50 day simple moving average is $17.68 and its 200-day simple moving average is $16.62.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. The business had revenue of $48.63 million for the quarter, compared to the consensus estimate of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. On average, equities analysts anticipate that SiBone will post -0.78 earnings per share for the current year.

Insider Transactions at SiBone

In other SiBone news, CEO Laura Francis sold 5,412 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $19.49, for a total value of $105,479.88. Following the completion of the sale, the chief executive officer owned 490,987 shares in the company, valued at $9,569,336.63. This trade represents a 1.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Anthony J. Recupero sold 3,310 shares of the company's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $18.27, for a total transaction of $60,473.70. Following the completion of the transaction, the insider owned 279,121 shares in the company, valued at approximately $5,099,540.67. This represents a 1.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,218 shares of company stock valued at $1,121,435. 4.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On SiBone

A number of hedge funds and other institutional investors have recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd acquired a new position in SiBone in the first quarter valued at $34,000. Virtus Fund Advisers LLC bought a new stake in SiBone in the 4th quarter valued at about $40,000. GAMMA Investing LLC boosted its holdings in shares of SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after acquiring an additional 3,867 shares during the period. Virtus Advisers LLC bought a new stake in shares of SiBone during the 1st quarter valued at $58,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of SiBone during the 4th quarter valued at $97,000. Institutional investors and hedge funds own 98.11% of the company's stock.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.